{
    "clinical_study": {
        "@rank": "125883", 
        "arm_group": [
            {
                "arm_group_label": "BYM338", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will assess the pharmacodynamics, pharmacokinetics, safety and tolerability of\n      BYM338 in patients with COPD and cachexia.  The primary outcome will be a change in thigh\n      muscle volume compared to placebo.  The study will last for approximately 24 weeks."
        }, 
        "brief_title": "BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Obstructive Pulmonary Disease (COPD) With Cachexia", 
        "condition_browse": {
            "mesh_term": [
                "Cachexia", 
                "Lung Diseases", 
                "Respiration Disorders", 
                "Pulmonary Disease, Chronic Obstructive", 
                "Lung Diseases, Obstructive"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Written informed consent must be obtained before any assessment is performed.\n\n          -  Males and females ages 40 to 80 years\n\n          -  Smoking history of at least 10 pack-years\n\n          -  Diagnosis of COPD according to GOLD guidelines (GOLD, 2010), with a\n             post-bronchodilator FEV\u00ac1 < 80% predicted and FEV1/FVC ratio < 0.70\n\n          -  BMI <20 kg/m2 or skeletal muscle mass index by DXA < 7.25 kg/m2 for men or <5.45\n             kg/m2 for women.\n\n          -  In general stable health, including managed COPD, by past medical history, physical\n             examination, vital signs at baseline as determined by the investigator.\n\n        Exclusion criteria:\n\n          -  Patients with MRC dyspnoea grade 5 (i.e. patients too breathless to leave the house\n             or breathless when dressing)\n\n          -  Plans for lung transplantation or lung reduction surgery within four months of\n             enrollment\n\n          -  Patients participating in a formal pulmonary rehabilitation program within 3 months\n             of dosing\n\n          -  History of malignancy of any organ system (other than excised non-melanomatous\n             carcinoma of the skin), treated or untreated, within the past 5 years, regardless of\n             whether there is evidence of local recurrence or metastases.\n\n          -  Diseases other than cancer known to cause cachexia or muscle atrophy, including but\n             not limited to congestive heart failure of any stage, chronic kidney disease\n             (estimated GFR < 30 mL/min using the MDRD equation), rheumatoid arthritis, primary\n             myopathy, stroke, HIV infection, tuberculosis or other chronic infection,\n             uncontrolled diabetes mellitus, etc.\n\n          -  Inflammatory bowel disease, celiac disease, short bowel syndrome, pancreatic\n             insufficiency\n\n          -  Use of any prescription drugs known to affect muscle mass, including androgen\n             supplements, anti-androgens (such as LHRH agonists), anti-estrogens (tamoxifen, etc.)\n             recombinant human growth hormone (rhGH), insulin, oral beta agonists, megestrol\n             acetate, dronabinol, metformin, etc.\n\n          -  Hemoglobin concentration below 11.0 g/dL at screening.\n\n          -  Liver disease or liver injury.\n\n          -  Use of other investigational drugs at the time of enrollment, or within 30 days and\n             for any other limitation of participation in an investigational trial based on local\n             regulations.\n\n          -  Women of child-bearing potential.\n\n        Other protocol-defined inclusion/exclusion criteria may apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "80 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 1, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01669174", 
            "org_study_id": "CBYM338X2204", 
            "secondary_id": "2011-000461-12"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BYM338", 
                "description": "BYM338", 
                "intervention_name": "BYM338", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Chronic Obstructive Pulmonary Disease", 
            "COPD; cachexia; muscle wasting"
        ], 
        "lastchanged_date": "March 26, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Torrance", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90502"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Waterbury", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06708"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Savannah", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "31419"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Terminated"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Normal", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "61761"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Missoula", 
                        "country": "United States", 
                        "state": "Montana", 
                        "zip": "59808"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "452242"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43213"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Spartanburg", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29303"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Maastricht", 
                        "country": "Netherlands", 
                        "zip": "6211"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bucharest", 
                        "country": "Romania", 
                        "zip": "Sector 5"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leicester", 
                        "country": "United Kingdom", 
                        "zip": "LE1 5WW"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "SW 6NP"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Machester", 
                        "country": "United Kingdom", 
                        "zip": "M23 9QZ"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Netherlands", 
                "Romania", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double Blind, Placebo Controlled, Multi-centre Study to Asses the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of BYM338 in Chronic Obstructive Pulmonary Disease Patients With Cachexia", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "1-888-669-6682"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone_ext": "+41613241111"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "Netherlands: Medicines Evaluation Board (MEB)"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in thigh muscle volume compare to placebo as measured by MRI", 
            "safety_issue": "No", 
            "time_frame": "24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01669174"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in 6 minute walk distance compared to placebo", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Safety and tolerability of BYM338 in COPD patients with cachexia", 
                "safety_issue": "Yes", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Pharmacokinetic profile and immunogenicity response to BYM338 in COPD patients with cachexia", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Number of participants with adverse events as a measure of safety and tolerability of BYM338 in COPD patients with cachexia", 
                "safety_issue": "Yes", 
                "time_frame": "24 weeks"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}